SAC Capital Advisors loaded up on shares of InterMune, a pharmaceutical company, when it looked like the company's hotly anticipated new drug would get approval from the Food and Drug Administration. But when the FDA rejected the drug and the stock plunged 80% in one day, the prognosis for that
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.